- Conditions
- Melanoma
- Interventions
- Encorafenib, Binimetinib, Pembrolizumab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 257 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 27
- States / cities
- Orlando, Florida • Fairway, Kansas • Overland Park, Kansas + 16 more
Therapy Directory
Pembrolizumab clinical trials
Directory of U.S. ClinicalTrials.gov public records that list Pembrolizumab as a study intervention. Browse Pembrolizumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1847
Shown on this page
12
Current sort
Recently updated
Therapy scope
Pembrolizumab
Additional filters apply within this therapy.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 385–396 of 1,847 matching trials for Pembrolizumab.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Advanced Cancer
- Interventions
- FLX475 (tivumecirnon), pembrolizumab (KEYTRUDA®)
- Drug
- Lead sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 19
- States / cities
- Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more
- Conditions
- Solid Tumors
- Interventions
- mRNA-4157, Pembrolizumab, SoC Treatment
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more
- Conditions
- Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C, Metastatic Lung Cancer, Advanced Lung Carcinoma
- Interventions
- BBO-8520, Pembrolizumab, BBO-10203
- Drug
- Lead sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 19 more
- Conditions
- Microsatellite Stable Metastatic Colorectal Cancer
- Interventions
- Evorpacept (ALX148), Cetuximab, Pembrolizumab
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Aurora, Colorado • New Brunswick, New Jersey + 1 more
- Conditions
- Recurrent Glioblastoma, Recurrent Gliosarcoma
- Interventions
- Laboratory Biomarker Analysis, Pembrolizumab, Pharmacological Study, Therapeutic Conventional Surgery
- Other · Biological · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma
- Interventions
- Pembrolizumab Monotherapy, Ramucirumab, Paclitaxel
- Drug
- Lead sponsor
- Harry H Yoon
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Milwaukee, Wisconsin
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Lenvatinib, Pembrolizumab, Oral Placebo, IV Placebo, TACE
- Drug · Biological · Procedure
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 22 more
- Conditions
- Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
- Interventions
- Ramucirumab, Paclitaxel, Sacituzumab Tirumotecan, Rescue Medications, HER3-DXd
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more
- Conditions
- Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Interventions
- Surgical Procedure, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Docetaxel, Vinorelbine, Nivolumab, Pembrolizumab, Atezolizumab, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 415
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 319 more
- Conditions
- Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck, Unresectable Head and Neck Squamous Cell Carcinoma
- Interventions
- Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy
- Combination Product · Drug
- Lead sponsor
- PDS Biotechnology Corp.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Greenbrae, California • Orange, California + 24 more
- Conditions
- Melanoma Stage III, Melanoma Stage IV
- Interventions
- L19IL2, L19TNF, L19IL2/L19TNF, KEYTRUDA®
- Drug
- Lead sponsor
- Philogen S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Hartford, Connecticut • New York, New York
About this Pembrolizumab clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Pembrolizumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
- How to narrow results
- Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pembrolizumab.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Pembrolizumab.